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HOW DOES AN 11-POINT PAIN SCALE RELATE
TO PREFERENCE ESTIMATES IN PATIENTS
WITH CHRONIC PAIN AND CAN IT BE USED TO
PREDICT PREFERENCES?
Lee TA1, Raymundo AL2, Kim SS3, Strauss M3, Sullivan SD4
1Hines VA Hospital, Hines, IL, USA; 2Pharmacia, Corp, Peapack,
NJ, USA; 3Purdue Pharma L.P, Stamford, CT, USA; 4University
of Washington, Seattle, WA, USA
OBJECTIVES: An 11-point pain scale from 0 (No Pain)
to 10 (Worst Possible Pain) is a frequent outcome measure
in pain studies. The measure is easily administered, under-
standable and useful in many diseases in which pain is a
factor. However, results from pain scales are difﬁcult to
compare with results from alternative outcome measures
when making policy decisions across diseases. Our objec-
tive was to examine the relation between an 11-point pain
scale and preferences and evaluate the performance of the
scale in estimating preferences. Thereby, possibly provid-
ing a method to estimate preferences in studies including
an 11-point pain scale but no direct preference measure.
METHODS: We used data from two clinical trials of
patients with chronic low back pain (N = 382). Patients
were divided into an estimation (N = 287) and validation
(N = 95) sample. At follow-up visits, patients completed
an 11-point pain scale and the EuroQol (EQ-5D).
RESULTS: In the overall cohort, average preference
values in four categories of pain were 0.843 (SD = 0.201)
for No Pain, 0.626 (SD = 0.226) for Mild, 0.492 (SD =
0.282) for Moderate and 0.245 (SD = 0.314) for Severe.
A regression model from the estimation sample provided
preference estimates for Mild pain of 0.628 and differ-
ences from that value were 0.172 for No Pain, -0.135 for
Moderate pain, and -0.387 for Severe pain. When these
values were applied to the validation sample, absolute dif-
ferences between actual and predicted preferences for the
pain categories ranged from 0.003 to 0.129. Generally,
the prediction methods did reasonably well at predicting
group averages, however the methods did not accurately
predict individual preferences. CONCLUSIONS: Our
ﬁndings provide investigators a reasonable method for
estimating preferences in studies including an 11-point
pain scale but no preference measure. However, the prop-
erties of these estimates need to be evaluated in other
patient populations and are only a second-best alterna-




PAIN: CHOICE OF METHOD MATTERS
Araki SS1, Kuntz KM1, Llewellyn-Thomas H2,Weinstein MC1,
Hornstein MD3,Tosteson ANA2
1Harvard School of Public Health, Boston, MA, USA;
2Dartmouth Medical School, Hanover, NH, USA; 3Brigham
and Women’s Hospital, Boston, MA, USA
OBJECTIVES: To assess the validity of patient prefer-
ence assessments of short-term health states associated
with endometriosis pain treatments; and to compare indi-
vidual treatment recommendations generated by a deci-
sion-analytic model incorporating patients’ rating scale
(RS) versus modiﬁed time tradeoff (mTTO) values.
METHODS: Seventy patients with endometriosis pain
valued nine health states associated with 3 equally-
effective treatments with different side effect proﬁles
(danazol, GnRH agonist, laparoscopy), using RS and
mTTO with sleep as the trading metaphor. With mTTO,
subjects chose between spending the next month in each
health state versus spending X days “asleep” (an unrest-
ful period of time one would miss) and 30-X days in good
health with no symptoms. We examined the internal and
across-method consistency of the valuations by checking
for violations of logical adherence (valuing states with
increasing adverse effects progressively worse) and pro-
cedural invariance (consistent rank ordering of states
across assessment methods). Finally, we incorporated
individual patients’ valuations into a decision-analytic
model and assessed the concordance of treatment recom-
mendations based on mTTO and RS values (converted
into utilities with a power transformation). RESULTS:
Mean mTTO values in order of increasing side effects
were: danazol -0.96, 0.80, 0.58, 0.47; GnRH agonist -
0.97, 0.78, 0.59; laparoscopy -0.77, 0.48. The vast
majority of subjects (97% with RS; 99% with mTTO)
consistently valued states with increasing morbidity pro-
gressively worse; and 97% valued each treatment’s health
states in a consistent rank order with RS and mTTO.
Based on mTTO valuations, individual treatment recom-
mendations were: 42% laparasocpy, 38% danazol, and
20% GnRH agonist. However, recommendations based
on transformed RS values differed for 49% of subjects.
CONCLUSIONS: Both RS and mTTO demonstrated
internal and across-method consistency in assessing the
temporary health states associated with endometriosis
treatments. However, the choice of assessment method
can greatly affect decision-analytically derived treatment
recommendations made to individual patients.
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AGE AND GENDER-STRATIFIED DIFFERENCES
IN QUALITY OF LIFE IN ELDERLY CHRONIC
PAIN PATIENTS
Oderda L, Stockdale B, Oderda GM, Donaldson G,
Ashburn M, Brixner D, Lipman A
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: Chronic pain is common in older patients.
Data are presented from the University of Utah Pain 
Management Center (PMC) to compare HRQoL in older
chronic pain patients with younger patients. METHODS:
Patients at the PMC are administered the TOPS (Total
Outcome of Pain Scale), a pain enhanced SF-36 that is
more sensitive and speciﬁc for chronic pain HRQoL out-
285Abstracts
comes. It is a 60-item questionnaire that contains the SF-
36 plus Pain Symptom, Functional Limitations, Perceived
Family/Social Disability, Real Family/Social Disability
and Formal Work Disability scales. RESULTS: Five 
thousand two hundred thirty-ﬁve TOPS instruments were
completed in 3,637 PMC patients from 1997 to 2002.
4,511 are <65 years, 392 are 65–74, and 332 are 75+.
Psychometric performance, evaluated with Cronbach’s
alpha index of internal consistency reliability, of the SF-
36/TOPS scales in this elderly population was consist-
ent with published validation standards. SF-36 Physical
Component Summary (PCS), Mental Component
Summary (MCS) and the TOPS Total Pain Experience
scales (TPE, a composite of 7 TOPS scales), for chronic
pain patients <65, 65–74 and >75 are: PCS (29.6, 27.9,
26.4), MCS (39.7, 42.2, 42.9), and TPE (60, 58.8, 61.1).
The PCS and MCS were signiﬁcantly different (p < 0.05)
when patients <65 were compared with older patients.
Top 5 ICD9 diagnoses in each age group accounted for
52–60% of diagnoses reported, with myalgia and myosi-
tis (729.1) and lumbago (724.2) being ﬁrst and second
ranked in each age group. Neuralgia, neuritis and radi-
culitis incidence was in the top ﬁve reported ICD9 diag-
noses for both older age groups, while herpes zoster
complications was reported only in the 75+ age group.
Inﬂuence of gender and work disability were also ana-
lyzed and will be presented. CONCLUSIONS: Older
chronic pain patients have a higher PCS, lower MCS,
similar TPE, and different diagnoses, as compared with
younger patients.
URINARY & KIDNEY DISEASES/DISORDERS—
Clinical Outcomes/Healthcare Policy
PRK1
COMPARISON OF DIRECT HEALTH-CARE COST,
HOSPITAL UTILIZATION AND MEDICATION
PERSISTENCE BETWEEN EXTENDED RELEASE
FORMS (ER) OF TOLTERODINE AND
OXYBUTYNIN IN OVERACTIVE
BLADDER/URINARY INCONTINENCE PATIENTS
Yu YF1,Yu AP2,Ahn J1, Nichol MB1
1University of Southern California, Los Angeles, CA, USA;
2USC School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: Tolterodine-ER is a newly-released 
medication for Overactive Bladder/Urinary Incontinence
(OAB/UI). This retrospective study investigated the dif-
ference in direct health-care cost, hospital utilization, and
medication persistence between OAB/UI patients initiated
with tolterodine-ER or oxybutynin-ER. METHODS:
Newly started adult patients (age > = 18) on either
tolterodine-ER or oxybutynin-ER from October 2001 to
May 2002 with 1-year washout period, were included
and followed up until the end of study period or disen-
rollment. The log-transformed direct healthcare cost
(excluding OAB-related pharmacy cost per member per
month) was analyzed by ANCOVA. Control variables
include demographics, previous hospital utilizations,
medication pattern, prior OAB diagnosis and comorbidi-
ties. A Cox Proportional Hazard model was applied to
examine the effect of different initial treatments on per-
sistence described by time to switch and time to discon-
tinuation. Logistic regression was used to assess the risk
of hospitalization associated with the ﬁrst prescription.
RESULTS: Of 1811 patients, 1021 patients started 
with tolterodine-ER, and 790 with oxybutynin-ER. The
average follow-up period for both groups was ﬁve
months. No signiﬁcant difference was found in the 
converted adjusted costs PMPM between tolterodine-ER
group (US$602) and oxybutynin-ER group (US$648)
with P = 0.324. Two groups had similar physician
encounter frequency (one visit PMPM) and emergency
room visit rate (2%), but tolterodine-ER initiated patients
were less frequently hospitalized (9.11% vs. 13.16%, P =
0.006). A higher proportion of oxybutynin-ER initiated
patients discontinued (56.6% vs. 52.5 %, P = 0.08) and
switched (7.85% vs. 7.54%, P = 0.808). The type of
initial therapy did not signiﬁcantly affect time to discon-
tinuation or time to switch, but initiating tolterodine-ER
could reduce the probability of hospitalization by 32%
(OR: 0.677, P = 0.037). CONCLUSIONS: Initial drug
selection did not signiﬁcantly change direct healthcare
cost, medical utilization, and medication persistence in
OAB/UI patients. However, patients initiating with oxy-
butynin-ER were exposed to a higher risk of hospitaliza-
tion than those initiating with tolterodine-ER.
PRK2
FACTORS ASSOCIATED WITH DIALYSIS
TREATMENT COSTS AMONG MEDICARE
ENROLEES
Beilfuss CD1, Hirth RA2
1University of Michigan and Pﬁzer Inc, Ann Arbor, MI, USA;
2University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Kidney failure affects approximately
300,000 people within the United States who require dial-
ysis therapy. Health care for affected patients is mainly
provided through the Medicare program. The literature
has shown that kidney failure has a signiﬁcant emotional,
psychological and ﬁnancial impact on affected patients
and society. There could be several factors that determine
patient utilization costs. Our objective is to identify the
demographic, clinical, and treatment facility factors that
signiﬁcantly explain the costs associated with kidney
failure treatment. METHODS: The study sample con-
sisted of 47,285 Medicare eligible dialysis patients. Data
were extracted for a 1-year period (1999). Predictor vari-
ables included patient demographics, treatment facility,
and several other kidney related laboratory test values
(such as creatinine clearance rates, co-morbidities, BUN,
and hematocrit at baseline). Outcome variables included
the dialysis treatment costs for epoetin and iron injec-
